Day: December 14, 2020

VANCOUVER, British Columbia, Dec. 14, 2020 (GLOBE NEWSWIRE) — Gold Bull Resources Corp. (TSX-V: GBRC) (“Gold Bull” or the “Company”) is pleased to announce it has completed the Sandman Project (“Sandman”) purchase from Newmont. Sandman is located in Nevada, USA and has been purchased for USD $4 million.Sandman includes a resource estimate of 309,900 ounces of gold (comprising of 217,900 oz Au in the Measured and Indicated Category plus an Inferred Resource of 38,000 oz Au as per 2007 NI 43-101 Resource Estimate).Gold Bull CEO, Cherie Leeden commented:For additional information please refer to the announcement dated October 12, 2020, titled ‘Gold Bull Executes Agreement to Acquire Sandman Project from Newmont.’Qualified PersonCherie Leeden, B.Sc Applied Geology (Honours), MAIG, a “Qualified Person” as defined by National Instrument...

VANCOUVER, British Columbia, Dec. 14, 2020 (GLOBE NEWSWIRE) — Prospect Park Capital ‎ Corp. (the “Company”) ‎‎(TSXV:PPK), announces a proposed non-brokered private ‎placement for gross proceeds of up to $1,000,000 through the issuance ‎of up to 5,555,555 common shares of the ‎Company at $0.18 per share (the “Offering”). The net proceeds of the Offering will be used by the Company for working capital.‎In connection with the issue and sale of the shares pursuant to the Offering, the Company will pay registered dealers ‎and finders (i) a cash commission equal to 8% of the aggregate gross proceeds under the Offering, and (ii) non-‎transferable compensation options to purchase that number of common shares as is equal to 8% of the number of common shares sold under the Offering, at an exercise price of $0.18 per share exercisable for a...

Commercial Launch of Ergonomix2 Planned for 2021Approval Accelerates Path to Europe for Motiva MiaPre-Commercial European Mia Procedures to Begin in Second Half of 2021SANTA BARBARA, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) — Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it has received a CE mark for its next generation Motiva Ergonomix2® silicone breast implant platform. The CE mark also includes the Motiva Ergonomix2 Diamond® breast implant, which is the implant that will be used in the Motiva Mia® minimally invasive breast augmentation system when it is approved.Ergonomix2 incorporates the latest innovations by Establishment Labs, including its most advanced ultra-high purity chemistries for enhanced...

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announces that it anticipates data safety monitoring board (DSMB) verbal feedback by the end of December 15, 2020 on interim data from the Company’s pivotal Phase 3 CardiAMP Heart Failure Trial that is currently enrolling nationwide for infusion of BioCardia’s CardiAMP™ autologous cell therapy to the myocardium. The DSMB is then anticipated to provide its written feedback approximately 24 hours later. BioCardia plans to provide an announcement pre-market on December 17, 2020 summnarizing the feedback and outlining the next resulting steps.  The CardiAMP Heart Failure study has been approved by the FDA to enroll up to 260 patients at up to 40 centers. The purpose of the study is to determine the safety and efficacy...

THE WOODLANDS, Texas, Dec. 14, 2020 (GLOBE NEWSWIRE) — Conn’s, Inc. (NASDAQ: CONN) (“Conn’s” or the “Company”) today announced the early results of its previously announced cash tender offer (the “tender offer”) to purchase up to $100.0 million (the “Aggregate Maximum Tender Amount”) aggregate principal amount of outstanding 7.250% senior notes due 2022 (the “notes”). The terms and conditions of the tender offer are set forth in the Offer to Purchase, dated November 30, 2020 (the “Offer to Purchase”). The tender offer will expire at 11:59 p.m., New York City time, on December 28, 2020, unless extended or earlier terminated by Conn’s.As of 5:00 p.m., New York City time, on December 11, 2020 (such time and date, the “Early Tender Deadline”), according to information provided by D.F. King & Co., Inc., the tender and information...

–Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications––Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic regimens, along with six patent applications––Contributes expanding library of psychedelic derivative drug development candidates, with the first lead compounds expected to enter clinical studies in 2021––Adelia leadership bring extensive clinical and commercialization experience of major drugs, including Allegra (fexofenadine), Sabril (vigabatrin), Anzemet (dolasetron), and Vaniqa (eflornithine)–TORONTO, Dec. 14, 2020 (GLOBE NEWSWIRE) — Cybin Inc. (NEO:CYBN) (“Cybin”), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased...

DALLAS, Dec. 14, 2020 (GLOBE NEWSWIRE) — Capital Senior Living Corporation (the “Company” or “Capital Senior Living”) (NYSE: CSU), one of the nation’s largest operators of senior housing communities, announced that its communities are included in the U.S. Department of Health and Human Services’ first priority phase for receiving the COVID-19 vaccine.The Centers for Disease Control and Protection (CDC) and its Advisory Committee on Immunization Practices (ACIP) have prioritized residents and staff members of long-term care facilities, at no cost to them. Residents and employees of the Company’s independent living, assisted living and memory care communities are included in Group 1A and will be in the first wave of vaccinations.As part of the CDC’s Pharmacy Partnership for Long-Term Care Program, Capital Senior Living will...

The Dissident Nominees would serve one shareholder, Fahad Al-Tamimi, who has no plan, omitted key facts and suggested an Investor Relations Officer as the CEO. Mason Graphite encourages shareholders to consider the facts in order to make an informed voting decision.Do not let Al-Tamimi take over the Company without paying a premium to shareholders. Shareholders are encouraged to vote FOR Management’s Director Nominees and to not support Al-Tamimi’s questionable hand-picked slate.If shareholders have already voted in favor of Al-Tamimi based on inaccurate information provided to them, they can change their vote by simply voting again using Management’s proxy prior to December 23, 2020 at 10:00 a.m. (Eastern Time).Shareholders who have questions or require voting assistance should contact Laurel Hill Advisory Group at 1-877-452-7184 or...

Les nominés proposés serviraient les intérêts d’un seul actionnaire, Fahad Al-Tamimi, qui ne dispose d’aucun plan, qui a omis de mentionner des faits clés et qui a proposé comme Président et Chef de la direction un officier responsable des relations avec les investisseurs. Mason Graphite encourage les actionnaires à considérer tous les faits afin de voter de façon éclairée.Ne laissez pas Al-Tamimi prendre le contrôle de la Société sans payer une prime aux actionnaires. Les actionnaires sont encouragés à voter POUR les candidats proposés par la Direction et à ne pas supporter la liste douteuse de nominés choisis par Al-Tamimi dans son seul intérêt.Si des actionnaires ont déjà voté en faveur d’Al-Tamimi en se basant sur l’information erronée qu’il leur a fournie, ils peuvent toujours modifier leur vote simplement en votant à nouveau, en...